| Title |
Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, September 2012
|
| DOI | 10.2147/ceor.s35194 |
| Pubmed ID | |
| Authors |
Giuliano Rizzardini, Umberto Restelli, Paolo Bonfanti, Emanuele Porazzi, Elena Ricci, Emanuela Foglia, Laura Carenzi, Davide Croce |
| Abstract |
In recent years, the increased efficacy and effectiveness of antiretroviral treatment has led to longer survival of patients infected with human immunodeficiency virus (HIV), but has also raised the question of what happens to consumption of resources. Early highly active antiretroviral treatment (HAART), management of hepatitis C virus (HCV) coinfection, and expensive newly marketed drugs may affect the economic sustainability of treatment from the point of view of the National Healthcare Services. The present study aimed to provide information on the economic burden of HIV-positive patients resident in the Lombardy region using a three-year time horizon. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 5 | 21% |
| Other | 4 | 17% |
| Student > Master | 3 | 13% |
| Student > Bachelor | 3 | 13% |
| Researcher | 2 | 8% |
| Other | 3 | 13% |
| Unknown | 4 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 38% |
| Economics, Econometrics and Finance | 3 | 13% |
| Agricultural and Biological Sciences | 3 | 13% |
| Nursing and Health Professions | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 4 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2012.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#385
of 514 outputs
Outputs of similar age
#143,349
of 188,508 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#5
of 7 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 514 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,508 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.